medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Number 1

<< Back Next >>

Ann Hepatol 2004; 3 (1)

Side effects of medical therapy for chronic hepatitis C

Shiffman ML

Language: English
References: 39
Page: 5-10
PDF size: 57.00 Kb.


ABSTRACT

The treatment of chronic hepatitis C virus (HCV) has improved greatly over the past decade. Over half of all patients treated with the combination of peginterferon and ribavirin have the opportunity to achieve sustained virologic response. The major factors which interfere with this goal are the side effects of therapy which require that the doses of peginterferon or ribavirin be reduced or that these medications be discontinued. While some of these side effects can be overcome and treatment continued, some side effects are severe and potentially life threatening. Appropriate recognition and management of these side effects will both improve response to therapy and avoid unnecessary morbidity and mortality.


REFERENCES

  1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.

  2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.

  3. Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadorl G, Bodenheimer Jr H, Bernstein D, Rizzetto M, Zeuzem S, Pockros P, Lin A, Ackrill AM. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Int Med 2004; 140: 346-355.

  4. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-S244.

  5. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.

  6. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, et al. Neutropenia during combination therapy of interferon and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-1279.

  7. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19(Suppl 1): 67-75.

  8. Shiffman ML, Hofmann CM, Sterling RK, Luketic VA, Contos MJ, Sanyal AJ. A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response. J Infect Dis 2001; 184: 405-409.

  9. Reed WW, Diehl LF. Leukopenia, neutropenia and reduced hemoglobin levels in healthy American blacks. Ann Intern Med 1991; 151: 501-505.

  10. Jacobsen. Neutropenia and infections abstract.

  11. Heathcote EJ, Shiffman ML, Cookesly WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.

  12. Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N. Effects of interferon alfa on peripheral neutrophil counts and serum granulocyte colony stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther 2000; 6: 149-154.

  13. Carreno V, Martin J, Pardo M, Brotons A, Anchia P, Navas S, Fernandez M, et al. Randomized controlled trial of recombinant human granulocyte macrophage stimulating factor for the treatment of chronic hepatitis C. Cytokine 2000; 12: 165-170.

  14. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5.

  15. Fujii H, Kitada T, Yamada T, Sakaguchi H, Seki S, Hino M. Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C. Hepatogastroenterology 2003; 50: 841-842.

  16. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, Gangl A, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123: 141-151.

  17. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.

  18. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G, et al. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001; 34: 911-916.

  19. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000; 18: 107-116.

  20. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440-446.

  21. Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. Psychol Med 2000; 30: 259-268.

  22. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-966.

  23. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672-676.

  24. Valentini P, Mariotti P, Ngalikpima CJ, Angelone DF, Ranno O. Seizures in an interferon-treated child. Dig Liver Dis 2001; 33: 363-365.

  25. Dalekos GN, Hatzis J, Tsianos EV. Dermatologic disease during interferon-alpha therapy for chronic viral hepatitis. Ann Intern Med 1998; 128: 409-410.

  26. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alfa: a case report and literature review. Muscle Nerve 2002; 25: 909-913.

  27. Stryjek-Kaminska D, Ochsendorf F, Roder C, Wolter M, Zeuzem S. Photoallergic skin reaction to ribavirin. Am J Gastroenterol 1999; 94: 1686-1688.

  28. Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002; 97: 2432-2440.

  29. Cadoni G, Marinelli L, De Santis A, Romito A, Manna R, Ottaviani F. Sudden hearing loss in a patient hepatitis C virus positive on therapy with interferon alfa: a possible autoimmune-microvascular pathogenesis. J Laryngol Otol 1998; 112: 962-963.

  30. Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996; 37: 905-915.

  31. Li SD, Yong S, Srinivas D, Van T. Reactivation of sarcoidosis during interferon therapy. J Gastroenterol 2002; 37: 50-54.

  32. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003; 13: 547-551.

  33. Saito H, Ebinuma H, Nagata H, Inagaki Y, Saito Y, Wakabayashi K, Takagi T, et al. Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C. Liver 2001; 21: 192-197.

  34. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.

  35. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; (in press).

  36. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 2491-2499.

  37. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers BJ. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; (in press).

  38. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Godman Z, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.

  39. Reddy KR, Wright TL, Pockros PJ, Shiffman ML, Everson G, Reindollar R, Fried MW, Purdum PP III, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J. Efficacy and safety of pegylated (40-KD) interferon a-2a compared with interferon a-2a in non-cirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438.




2020     |     www.medigraphic.com